Hansoh Pharmaceutical Shares Rise Nearly 5% on Clinical Trial Approvals for Multiple Drug Candidates

　　Hansoh Pharma(03692) Closed up 4.92% at HK$12.80, with a turnover of HK$44.43312 million.

Hansoh Pharma announced that the HS-10398 capsule has received the clinical trial notification issued by the China National Medical Products Administration, intended for the treatment of IgA nephropathy and membranous nephropathy; the HS-10501 tablet has received the clinical trial notification issued by the China National Medical Products Administration, intended for the treatment of type 2 diabetes and adult obesity; the HS-10509 tablet has received the clinical trial notification issued by the National Medical Products Administration of the People's Republic of China, intended for the treatment of schizophrenia.

Editor: Lu Yujun